homepage-top-section

The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK). With this agreement,

The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib. The global R&D-based biopharmaceutical company’s new drug

The US Food and Drug Administration (FDA) has granted priority review for Merck’s New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan. A candidate from

California-based biopharmaceutical company Gilead Sciences, Inc. and New Jersey-based Merck have announced their agreement to develop and commercialise the long-acting HIV treatments lenacapavir and islatravir. The treatments combine

Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan. Lanadelumab subcutaneous injection

A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for

Enveric Biosciences has announced that it has signed an exclusive, perpetual licensing agreement with Diverse Biotech to develop new molecules for the treatment of cancer and other debilitating

Eli Lilly and Company has signed a research collaboration and license agreement with Biolojic Design to discover and develop therapies for diabetes treatment. Under the deal, Biolojic’s artificial

Johnson & Johnson has secured authorisation for its Covid-19 vaccine under interim order (IO) from Health Canada for emergency use. Developed by the Janssen Pharmaceutical Companies of Johnson